ORIC Pharmaceuticals
ORIC Pharmaceuticals
ORIC
NASDAQ
7.88
USD
-1.50%
About
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies.
Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 327.8K |
| Three Month Average Volume | 11.7M |
| High Low | |
| Fifty-Two Week High | 16.65 USD |
| Fifty-Two Week Low | 5.27 USD |
| Fifty-Two Week High Date | 06 Mar 2024 |
| Fifty-Two Week Low Date | 13 Oct 2023 |
| Price and Volume | |
| Current Price | 10.37 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.09% |
| Thirteen Week Relative Price Change | 7.78% |
| Twenty-Six Week Relative Price Change | -35.67% |
| Fifty-Two Week Relative Price Change | -7.64% |
| Year-to-Date Relative Price Change | -4.82% |
| Price Change | |
| One Day Price Change | 1.67% |
| Thirteen Week Price Change | 15.35% |
| Twenty-Six Week Price Change | -29.26% |
| Five Day Price Change | 8.02% |
| Fifty-Two Week Price Change | 15.74% |
| Year-to-Date Price Change | 12.72% |
| Month-to-Date Price Change | -7.41% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.08431 USD |
| Book Value Per Share (Most Recent Quarter) | 4.46859 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.08431 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.46859 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.96436 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.95715 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.762 USD |
| Normalized (Last Fiscal Year) | -1.95715 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.95715 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.762 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.95715 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.762 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.79449 USD |
| Cash Per Share (Most Recent Quarter) | 4.23225 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.93709 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.73738 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.58985 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 21.30% |
| Tangible Book Value (5 Year) | 39.22% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 10.09% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 9.59% |
| EPS Change (Trailing Twelve Months) | 19.19% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -286,406,000 |
| Net Debt (Last Fiscal Year) | -208,187,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 10 |
| Current Ratio (Most Recent Quarter) | 15 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -86,537,000 |
| Free Cash Flow (Trailing Twelve Months) | -100,411,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -40.34% |
| Return on Assets (Trailing Twelve Months) | -35.69% |
| Return on Assets (5 Year) | -33.92% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -45.11% |
| Return on Equity (Trailing Twelve Months) | -38.79% |
| Return on Equity (5 Year) | -47.64% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -43.47% |
| Return on Investment (Trailing Twelve Months) | -37.77% |
| Return on Investment (5 Year) | -35.77% |